Given that both CRC cells and colonic macrophages overexpress MR on the surface28,29, mannose modification or mannosylation is efficient dual-targeting strategy and can be implanted into the design of CRC-specific nanomedicine. The gene discussed is NR3C2; the disease is colorectal carcinoma.